VIR (Vir Biotechnology) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VIR Vir Biotechnology Inc VIR
52 GF Score
Price $9.50
GF Value $42.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Vir Biotechnology Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

VIR
52GF Score
Vir Biotechnology Inc VIR
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vir Biotechnology (VIR) Overvalued in 2026?

Based on GuruFocus' analysis, Vir Biotechnology stock appears to be undervalued. The current stock price of $9.50 is trading 77.5% below its estimated GF Value™ of $42.20. GuruFocus considers Vir Biotechnology to be Possible Value Trap.

Key valuation signals for VIR:

  • Short Ratio:
  • GF Value™: $42.20 vs. price of $9.50 (77.5% below fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the VIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vir Biotechnology Business Description

Address 1800 Owens Street, Suite 900, San Francisco, CA, USA, 94158
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
52GF Score

Get the complete analysis for VIR

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.50
Price
$42.20
GF Value